SEARCH

SEARCH BY CITATION

References

  • 1
    Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:75768.
  • 2
    Rowe M, Zuo J. Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity. Microbes Infect 2010;12:17381.
  • 3
    Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003;3:80112.
  • 4
    Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004;10:80321.
  • 5
    Moss DJ, Burrows SR, Khanna R. EBV: immunobiology and host response. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, eds.Human herpesviruses: biology, therapy, and immunoprophylaxis.Cambridge:Cambridge University Press,2007. Chapter 51.
  • 6
    Crawford DH. Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci 2001;356:46173.
  • 7
    Chabay P, Burna V, Moar A, et al. Prevalencia de la infección por el virus de Epstein-Barr en pacientes pediátricos. Rev Hosp De Niños B Aires 1999;41:8891.
  • 8
    Hjalgrim H, Friborg J, Melbye M. The epidemiology of EBV and its association with malignant disease. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, eds.Human herpesviruses: biology, therapy, and immunoprophylaxis.Cambridge:Cambridge University Press,2007. Chapter 53.
  • 9
    Crawford DH, Swerdlow AJ, Higgins C, et al. Sexual history and Epstein-Barr virus infection. J Infect Dis 2002;186:7316.
  • 10
    Hjalgrim H, Friborg J, Melbye M. The epidemiology of EBV and its association with malignant disease. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, eds.Human herpesviruses: biology, therapy, and immunoprophylaxis.Cambridge:Cambridge University Press,2007. Chapter 53.
  • 11
    Crawford DH, Macsween KF, Higgins CD, et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clin Infect Dis 2006;43:27682.
  • 12
    Williams H, Macsween K, McAulay K, et al. Analysis of immune activation and clinical events in acute infectious mononucleosis. J Infect Dis 2004;190:6371.
  • 13
    Balfour HH Jr, Holman CJ, Hokanson KM, et al. A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis 2005;192:150512.
  • 14
    Lorenzetti MA, Gutiérrez MI, Altcheh J, et al. Epstein-Barr virus BZLF1 gene promoter variants in paediatric patients with acute infectious mononucleosis: its comparison with paediatric lymphomas. J Med Virol 2009;81:191217.
  • 15
    Silins SL, Sherritt MA, Silleri JM, et al. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood 2001;98:373944.
  • 16
    Harris N. The many faces of Hodgkin's disease around the world: what have we learned from its pathology?Ann Oncol 1998;9:S45S56.
  • 17
    Cader FZ, Kearns P, Young L, et al. The contribution of the Epstein-Barr virus to the pathogenesis of childhood lymphomas. Cancer Treat Rev 2010;36:34853.
  • 18
    Kapatai G, Murray P. Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma. J Clin Pathol 2007;60:134249.
  • 19
    Carbone A, Spina M, Gloghini A, et al. Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome. Am J Hematol 2011;86:1709.
  • 20
    De Matteo E, Barón AV, Chabay P, et al. Comparison of Epstein-Barr virus presence in Hodgkin lymphoma in paediatric versus adult Argentine patients. Arch Pathol Lab Med 2003;127:13259.
  • 21
    Chabay PA, Barros MH, Hassan R, et al. Paediatric Hodgkin lymphoma in 2 South American series: a distinctive epidemiologic pattern and lack of association of Epstein-Barr virus with clinical outcome. J Pediatr Hematol Oncol 2008;30:285291.
  • 22
    Barros MH, Vera-Lozada G, Soares FA, et al. Tumor microenvironment composition in paediatric classical hodgkin lymphoma is modulated by age and Epstein-barr virus infection. Int J Cancer 2012;131:114252.
  • 23
    Barros MH, Hassan R, Niedobitek G. Disease patterns in paediatric classical Hodgkin lymphoma: a report from a developing area in Brazil. Hematol Oncol 2011;29:1905.
  • 24
    Figueira-Silva Cecília M, Pereira Fausto EL. Prevalence of Epstein-Barr virus antibodies in healthy children and adolescents in Vitória, State of Espírito Santo, Brazil. Rev Soc Bras Med Trop 2004;37:40912.
  • 25
    Araujo I, Bittencourt AL, Barbosa HS, et al. The high frequency of EBV infection in paediatric Hodgkin lymphoma is related to the classical type in Bahia, Brazil. Virchows Arch 2006;449:31519.
  • 26
    Quintanilla-Martínez L, Gamboa-Domńquez A, Gamez-Ledesma I, et al. Association of Epstein-Barr virus latent membrane protein and Hodgkin's disease in Mexico. Mod Pathol 1995;8:6759.
  • 27
    Chang KL, Albújar PF, Chen YY, et al. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru. Blood 1993;81:496501.
  • 28
    Niens M, Jarrett RF, Hepkema B, et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 2007;110:331015.
  • 29
    Hjalgrim H, Rostgaard K, Johnson PC, et al. HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proc Natl Acad Sci USA 2010;107:64005.
  • 30
    Cairo MS, Raetz E, Lim MS, et al. Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future. Pediatr Blood Cancer 2005;45:75369.
  • 31
    Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005;131:3949.
  • 32
    Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958;46:21823.
  • 33
    Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol 2012;156:74456.
  • 34
    Kelly GL, Rickinson AB. Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematol Am Soc Hematol Educ Program 2007:277284.
  • 35
    Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007;110:9728.
  • 36
    Kuze T, Nakamura N, Hashimoto Y, et al. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(−) cases in Japanese population. Jpn J Cancer Res 2000;91:123340.
  • 37
    Adam P, Bonzheim I, Fend F, et al. Epstein-Barr virus-positive diffuse large B-cell lymphomas of the elderly. Adv Anat Pathol 2011;18:34955.
  • 38
    Swerdlow SH, Campo E, Harris NL, et al.WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn.Lyon, France:IARC Press,2008.
  • 39
    Chabay P, Lara J, Lorenzetti M, et al. Epstein Barr virus in relation to apoptosis markers and patients' outcome in paediatric B-cell non-Hodgkin lymphoma. Cancer Lett 2011;307:2216.
  • 40
    Hassan R, Klumb CE, Felisbino FE, et al. Clinical and demographic characteristics of Epstein-Barr virus-associated childhood Burkitt's lymphoma in South-eastern Brazil: epidemiological insights from an intermediate risk region. Haematologica 2008;93:7803.
  • 41
    Hjalgrim H, Smedby KE, Rostgaard K, et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res 2007;67:23828.
  • 42
    Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003;3:80112.
  • 43
    God JM, Haque A. Burkitt lymphoma: pathogenesis and immune evasion. J Oncol 2010;2010:114.
  • 44
    Brady G, MacArthur GJ, Farrell PJ. Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol 2007;60:1397402.
  • 45
    Bellan C, Lazzi S, Hummel M, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood 2005;106:10316.
  • 46
    Küppers R. Molecular biology of Hodgkin lymphoma. Hematol Am Soc Hematol Educ Program 2009:4916.
  • 47
    Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:27582.
  • 48
    Oschlies I, Klapper W, Zimmermann M, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 2006;107:404752.
  • 49
    Schaub B, Lauener R, von Mutius E. The many faces of the hygiene hypothesis. J Allergy Clin Immunol 2006;117:96977.
  • 50
    Smedby KE, Hjalgrim H, Chang ET, et al. Childhood social environment and risk of non-Hodgkin lymphoma in adults. Cancer Res 2007;67:1107482.